Supernus Pharmaceuticals, Inc.

Good afternoon and thank you for standing by. Welcome to the Nus Pharmaceuticals third quarter 2026 financial results conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Instructions will follow at that time. Please be advised that today's conference is being recorded. I now will hand the conference over to Peter Vosso of ICR Healthcare Investor Relationships Representative for Sopranos Pharmaceuticals. Please go ahead.

Thank you, Angela. Good afternoon, everyone, and thank you for joining us today for Sopranos Pharmaceuticals' third quarter of 2026 Financial Results Conference Call. Today, after the close of the market, the company issued a press release announcing these results. On the call with me today are Sopernos' Chief Executive Officer, Jack Khattar, and Chief Financial Officer, Tim Deck. Today's call is being made available via the investor relations section of the company's website at www.ir.sopernos.com. Before we begin, I'd like to remind you that we will be making forward-looking statements. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we and Indivia Pharmaceuticals have filed with the SEC, including in periodic reports under the heading risk factors, which identify important factors that could cause actual results to differ materially from those expressed by the company verbally, as well as statements made within this afternoon's press release. This call is being webcast live, and a link will be found at the Sopernos website at ir.sopernos.com, and a replay will be made available shortly after this call is concluded. I'll now turn the call over to Jeff.

Thank you, Peter. Good afternoon, everyone, and thanks for taking the time to join us on today's call. Today we will focus on Sopernos' strong 2026 third quarter and year-to-date results. which show the continued momentum across our commercial portfolio, specifically our growth products. After walking through these results, I'll provide a brief update on our transformative merger with Endivio Pharmaceuticals. For the third quarter of 2026, combined revenues of our growth products, Calvary, Zerzuve, Onetco, and GoCoverie increased by 43% compared to the same period last year. Starting with Calgary in the third quarter, prescriptions as reported by IQBier grew by 18% over the third quarter of 2025, outpacing the 10% growth in the ADHD market. Net sales were 91 million in the third quarter, representing a 12% increase over last year. Similarly, for the nine months ended September 30, 2026, Calvary achieved robust growth of 18% in prescriptions and 15% in net sales compared to the same period last year. Net sales for the nine-month period reach an all-time high of $258 million. Calvary's growth over the last year continues to come from both patient populations, with third-quarter adult prescription growth of 25% and pediatric prescription growth of 16%. In addition, the total quarterly number of prescribers for Calgary reached a high of approximately 46,000. Moving on to ANATCO during the third quarter of 2026, ANATCO generated net sales of $17.1 million, up 27% compared to the second quarter of 2026. Demand for the product continued to be healthy with more than 400 enrollment forms submitted in the quorum. In the third quarter of 2026, prescriptions grew by 17% compared to the second quarter of 2026. As we announced last week, the FDA has recognized seven years of orphan drug exclusivity for Monaco for the treatment of motor fluctuations in adults with advanced Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long underserved community. In addition, we submitted a supplemental new drug application to the FDA, the second source of supply, with approval expected by mid-year 2027. Switching to Zarzouvet, Sopernos reported $42 million in collaboration revenues in the third quarter and a hundred and five million dollars for the nine months period year to date. Full third quarter 2026 U.S. of Zerzuvae sales as reported by Biogen increased approximately by 53% compared to the same period in 2025. In the third quarter of 2026, Zerzuvae saw strong growth in demand with written prescriptions growing 43% and the number of prescribers growing 42% compared to the same period last year. Since launch, 87% of the prescriptions have come from repeat prescribers and more than 43,000 patients have been treated with Zirzuva. Switching now to recovery for the third quarter, the brand grew 4% in net sales and in prescriptions compared to the same period last year. Net sales reached an all-time high of $43 million in the third quarter. Moving on to R&D, the SPN820 and SPN817 Phase IIb studies continue to enroll subjects with major depressive disorder and focal seizures, respectively. The SPN443 program is expected to start the Phase I single ascending and multiple ascending dose study in adult healthy volunteers by the end of 2026. Now turning to the status of our transformative merger with Indivio Pharmaceuticals, I'm pleased to report that Supernus and Indivir shareholders voted to approve the merger on October 15, and we expect this transaction to close on November 2. As you may have seen earlier today, Indivir's results for the three months and nine months ended September 30, 2026 were also strong and driven by continued record performance of Sublocate. Combined with Soprano's solid performance and output, the new company will be starting from a position of strength with significant earnings and cash flow potential. The combined company will have a commercial portfolio of 11 differentiated medicines across psychiatry, neurology, and addiction, with key growth products currently expected to continue growing well into the 2030s. In addition, we will have the profitability, cash flow generation, and financial capacity to pursue further growth opportunities, including driving growth in our existing commercial portfolio, advancing our novel pipeline, and pursuing future business development. Our near-term priorities are to work through the integration of the two companies, ensure that our key growth drivers remain on track, and to progress our pipeline. Integration planning has been underway and we remain confident in capturing the $125 million of expected annual cost synergies that we previously discussed. With this merger on the verge of closing, we're entering an exciting new chapter that builds on a strong foundation. We expect to provide combined full-year 2027 guidance in February during the release of fourth quarter and full-year 2026 results. With that, I will now turn the call over to Tim.